Xilio Therapeutics, Inc. Insider Trading Activity
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Xilio Therapeutics, Inc. director Shannon James Samuel completed an open-market purchase of common stock. On March 26, 2026, Samuel bought 5,000 shares at a weighted average price of $8.79 per share, increasing direct holdings to 10,000 shares. The reported ownership reflects a 1-for-14 reverse stock split effective March 13, 2026.
Insider Trade Summary
Net Buyer: 5,000 shares
Net Buy
1 txn
Insider
Shannon James Samuel
Role
Director
Bought
5,000 shs ($44K)
Increase in Position
100%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,000 | $8.79 | $44K |
Holdings After Transaction:
Common Stock — 10,000 shares (Direct)
Holdings Before and After:
Common Stock, 5,000 to 10,000 shares (Direct)
Footnotes (2)
- F1. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $8.6758 to $9.2499, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- F2. The number of shares beneficially owned reflects the 1-for-14 reverse stock split effected March 13, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.